MELOXICAM | A077921 | ZYDUS PHARMACEUTICALS USA INC
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Suitability Petition from Pharmobedient Consulting, LLC FDA-2025-P-0343 · 9 docket documents Pharmobedient Consulting, LLC filed this suitability petition under section 505(j)(2)(C) of the Federal Food, Drug, and Cosmetic Act and 21 C.F.R. § 314.93 requesting that the FDA declare Meloxicam Tablets in 5 mg and 10 mg strengths suitable for submission in an Abbreviated New Drug Application, wi | Suitability | 2025-01-29 | DeniedDecision letter not yet read | Pharmobedient Consulting, LLC |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$0.0186
per ea
Lowest NADAC/Unit
$0.0165
per ea
Brand NDCs
0
Generic NDCs
7
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 68382005105MELOXICAM 15 MG TABLET | $0.0186 | EA | Generic | — | 2026-08-19 |
| 68382005101MELOXICAM 15 MG TABLET | $0.0186 | EA | Generic | — | 2026-08-19 |
| 82009013005MELOXICAM 15 MG TABLET | $0.0186 | EA | Generic | — | 2026-08-19 |
| 60687019901MELOXICAM 15 MG TABLET | $0.0186 | EA | Generic | — | 2026-08-19 |
| 68382005005MELOXICAM 7.5 MG TABLET | $0.0165 | EA | Generic | — | 2026-08-19 |
| 82009012905MELOXICAM 7.5 MG TABLET | $0.0165 | EA | Generic | — | 2026-08-19 |
| 68382005001MELOXICAM 7.5 MG TABLET | $0.0165 | EA | Generic | — | 2026-08-19 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.